A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 18, 2019

Primary Completion Date

December 6, 2021

Study Completion Date

June 24, 2022

Conditions
Epidermolysis Bullosa
Interventions
DRUG

Serlopitant Tablet

Serlopitant is a small molecule, highly selective NK1-R (neurokinin-1 receptor) antagonist. Two critical mediators of the urge to scratch are Substance P, or SP, and its receptor, NK1-R. SP is a naturally occurring peptide in the tachykinin neuropeptide family. Tachykinins have a broad range of functions in the nervous and immune systems. SP binding of NK1-R has been shown to be a key mediator of sensory nerve signaling, including the itch-scratch reflex and the vomiting reflex.

DRUG

Placebo Oral Tablet

The placebo is a tablet that looks like a drug but has no drug or other active ingredient in it.

Trial Locations (1)

94063

Stanford University, Redwood City

All Listed Sponsors
collaborator

Epidermolysis Bullosa Research Partnership

OTHER_GOV

collaborator

Vyne Therapeutics Inc.

INDUSTRY

lead

Stanford University

OTHER

NCT03836001 - A Neurokinin-1 Receptor Antagonist for the Treatment of Pruritus in Patients With Epidermolysis Bullosa | Biotech Hunter | Biotech Hunter